AVORO CAPITAL ADVISORS LLC 13D and 13G filings for Mirati Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 09:13 am Sale | 2023-12-31 | 13G | Mirati Therapeutics, Inc. MRTX | AVORO CAPITAL ADVISORS LLC | 4,886,840 7.000% | -668,715 (-12.04%) | Filing |
| 2023-02-14 09:34 am Purchase | 2022-12-31 | 13G | Mirati Therapeutics, Inc. MRTX | AVORO CAPITAL ADVISORS LLC | 5,555,555 9.600% | 480,555 (+9.47%) | Filing |
| 2022-02-11 10:01 am Purchase | 2021-12-31 | 13G | Mirati Therapeutics, Inc. MRTX | AVORO CAPITAL ADVISORS LLC | 5,075,000 9.200% | 540,000 (+11.91%) | Filing |
| 2021-02-12 08:00 am Purchase | 2020-12-31 | 13G | Mirati Therapeutics, Inc. MRTX | AVORO CAPITAL ADVISORS LLC | 4,535,000 9.020% | 621,565 (+15.88%) | Filing |
| 2020-02-14 10:00 am Purchase | 2019-12-31 | 13G | Mirati Therapeutics, Inc. MRTX | AVORO CAPITAL ADVISORS LLC | 3,913,435 9.910% | 100,200 (+2.63%) | Filing |